会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 82. 发明授权
    • Vector, element and method for inhibiting immune recognition
    • 用于抑制免疫识别的载体,元件和方法
    • US5750398A
    • 1998-05-12
    • US159890
    • 1993-11-30
    • David C. JohnsonIan A. York
    • David C. JohnsonIan A. York
    • G01N33/569A61K31/70A61K35/76A61K38/00A61K38/16A61K39/395A61K48/00A61P3/08A61P25/00A61P27/02A61P29/00A61P31/12A61P37/00A61P37/06C07H21/04C07K14/035C07K16/08C12N5/10C12N7/00C12N15/09C12N15/38C12P21/02C12R1/92G01N33/15G01N33/50C12N15/85C12N15/86
    • G01N33/505A61K38/162C07K14/005G01N33/5008G01N33/502G01N33/5044G01N33/5088A61K48/00C12N2710/16622G01N2333/035
    • This invention relates to the use of Herpes Simplex Virus (HSV) immediate early protein ICP47, nucleic acid sequences coding for ICP47, and homologous proteins and nucleic acid sequences, to inhibit presentation of viral and cellular antigens associated with major histocompatibility class I (MHC class I) proteins to CD8+ T lymphocytes; this inhibition effectively increases infective persistence, which can, for example, improve the utility of viral gene therapy vectors. This invention also pertains to a method for the treatment of herpesvirus infections, wherein expression and/or activity of the ICP47 protein or its homologue is inhibited in order to increase immune recognition of herpesvirus-infected cells and other cells. This invention also pertains to a method for identifying drugs that interfere with the expression or function of ICP47 and its homologues, and which are useful in treating herpesvirus infections, and also pertains to the drugs so identified. Furthermore, this invention pertains to methods for the treatment and prevention of autoimmune diseases, tissue and organ transplant rejection, diabetes, multiple sclerosis, arthritis, and tissue damage accompanying ocular herpesvirus infections, wherein ICP47 or its homologue, or nucleic acids encoding such proteins, are introduced into the cells of a patient. In addition, this invention pertains to vector elements, vectors, polypeptides and polypeptide fragments that can be utilized for the forgoing purposes.
    • 本发明涉及单纯疱疹病毒(HSV)立即早期蛋白ICP47,编码ICP47的核酸序列和同源蛋白质和核酸序列的用途,以抑制与主要组织相容性I类(MHC类别)相关的病毒和细胞抗原的呈递 I)蛋白对CD8 + T淋巴细胞; 这种抑制有效地增加感染持续性,其可以例如改善病毒基因治疗载体的效用。 本发明还涉及治疗疱疹病毒感染的方法,其中抑制ICP47蛋白或其同系物的表达和/或活性以增加疱疹病毒感染的细胞和其他细胞的免疫识别。 本发明还涉及用于鉴定干扰ICP47及其同源物的表达或功能的药物的方法,其可用于治疗疱疹病毒感染,并且还涉及所鉴定的药物。 此外,本发明涉及治疗和预防伴随眼疱疹病毒感染的自身免疫疾病,组织和器官移植排斥,糖尿病,多发性硬化,关节炎和组织损伤的方法,其中ICP47或其同源物或编码这种蛋白质的核酸, 被引入患者的细胞中。 此外,本发明涉及可用于前述目的的载体元件,载体,多肽和多肽片段。
    • 84. 发明授权
    • Burn-in socket testing apparatus
    • 老化插座测试仪
    • US5486771A
    • 1996-01-23
    • US363559
    • 1994-12-23
    • Keith L. VolzRobert M. RennRobert D. IrlbeckFrederick R. DeakDavid C. Johnson
    • Keith L. VolzRobert M. RennRobert D. IrlbeckFrederick R. DeakDavid C. Johnson
    • G01R31/26G01R1/04H01R33/76H01R33/97H05K7/10G01R31/02H05K1/02
    • H05K7/1023G01R1/0433
    • This invention is directed to a mechanical, robotically operated burn-in socket testing apparatus for integrated circuit "chips", where such chips, as known in the art, are typically planar electronic devices. The apparatus, operationally mounted to a planar electronic board, such as a mother board, comprises a first frame member for mounting to the mother board, where the first frame member includes electrical means for engaging chip leads and applying electrical current thereto during the burn-in testing. A second frame member is disposed in sliding engagement with the first frame member, where the second frame member is movable from a first position to a second position. Finally, cooperative latching and camming means are provided between the first and second frame members to effect the movement between the first and second positions, and to securely hold the chip during burn-in, where the camming means includes a pivotal member movable from a remote position free of the chip to a position engaging the chip.
    • 本发明涉及用于集成电路“芯片”的机械式机器人操作的老化插座测试装置,其中如本领域已知的这样的芯片通常是平面电子器件。 该装置可操作地安装在诸如母板的平面电子板上,包括用于安装到母板的第一框架构件,其中第一框架构件包括用于接合芯片引线并在燃烧期间向其施加电流的电气装置, 在测试。 第二框架构件设置成与第一框架构件滑动接合,其中第二框架构件可从第一位置移动到第二位置。 最后,协作锁定和凸轮装置设置在第一和第二框架构件之间以实现第一和第二位置之间的移动,并且在老化期间牢固地保持芯片,其中凸轮装置包括可从远程 位置没有芯片到与芯片接合的位置。
    • 86. 发明授权
    • Making amorphous and crystalline alloys by solid state interdiffusion
    • 通过固态相互扩散制备无定形和结晶合金
    • US5198043A
    • 1993-03-30
    • US734186
    • 1991-07-22
    • David C. Johnson
    • David C. Johnson
    • C22C1/00
    • C22C1/00
    • Methods for synthesizing solid-state crystalline alloys and products made therefrom are disclosed. Plural repeat units, each comprising an ordered sequence of superposed layers of preselected solid-state reactants, are formed superposedly on a surface of a solid substrate to form a modulated composite of the reactants. The layers comprising a repeat unit are controllably formed to have relative thicknesses corresponding to the stoichiometry of a preselected solid compound found on a phase diagram of the reactants. Each repeat unit also has a repeat-unit thickness no greater than a critical thickness for a diffusion couple of the reactants, where the repeat-unit thickness is preferably less than or equal to about 100 .ANG.. The modulated composite is then heated to an interdiffusion temperature lower than a nucleation temperature for the reactants for a time sufficient to form an amorphous alloy of the reactants having a stoichiometry corresponding to the preselected solid compound. The amorphous alloy is then heated to a nucleation temperature to initiate crystallization of the alloy. The methods described herein allow control of the outcome of a solid-state synthesis pathway in part by controlling which intermediate(s) are formed.
    • 公开了用于合成固态结晶合金和由其制成的产品的方法。 在固体基材的表面上叠加地形成多个重复单元,每个重复单元包含预选的固态反应物的叠层的有序序列,以形成反应物的调制复合物。 包含重复单元的层可控制地形成为具有对应于在反应物的相图上发现的预选的固体化合物的化学计量的相对厚度。 每个重复单元还具有不大于反应物的扩散偶的临界厚度的重复单元厚度,其中重复单元厚度优选小于或等于约100埃。 然后将调制的复合物加热到低于反应物的成核温度的相互扩散温度足以形成具有对应于预选固体化合物的化学计量的反应物的非晶态合金的时间。 然后将非晶合金加热至成核温度以引发合金的结晶。 本文描述的方法允许部分地通过控制形成中间体来控制固态合成途径的结果。